| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a143113a8426bd57def2ea84d70df56 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87 |
| filingDate |
2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baa50896e24a14969754d6b351f1fe5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_768ba8a3497a0d163849950675dbe919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6b6fd85aea4860ad31a1bc9fe09cd7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5fe36a2614e8931d90b699fa91727f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da6be7bb5a41a9311af847157bfa1500
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c0a137f5718a227c21c169f4b4d96d6 |
| publicationDate |
2022-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022243540-A1 |
| titleOfInvention |
Lentivirus-derived nanoparticles comprising crispr/cas9 ribonucleoprotein complexes |
| abstract |
The present invention relates to a lentivirus-derived particle comprising one or more Cas9-like proteins and at least one optimized sgRNA, wherein the optimized sgRNA comprises a targeting region and a non-targeting region, wherein said non-targeting region comprises a nucleotide sequence corresponding to SEQ ID NO: 1 or sequences having at least 90% sequence identity to SEQ ID NO: 1, said nucleotide sequence further comprising at least the following modifications: an extended repeat-anti-repeat region comprising a first extension of 2-8 base pairs in the repeat-anti-repeat region corresponding to nucleotides 1-12 and 17-30 of SEQ ID NO: 1; and optionally, an extended stem-loop 2 region comprising a second extension of 2-8 base pairs in the stem-loop 2 corresponding to the nucleotides 48-61 of SEQ ID NO: 1; and/or optionally, an A-U flip of the nucleotides corresponding to nucleotides 5 and 36 of SEQ ID NO: 1. |
| priorityDate |
2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |